Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin

European Journal of Cancer

Volumn 37, Issue 7, 2001, Pages 878-883

  Hengge, U R ^a   Esser, S ^a   Rudel, H P ^a   Goos, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

CD4 cells; Chemotherapy; Hepatotoxicity; HIV; HIV RNA; Kaposi's sarcoma; Leucopenia; Pegylated liposomal doxorubicin

Indexed keywords

BLEOMYCIN; CD4 ANTIGEN; CYTOSTATIC AGENT; DOXORUBICIN; DOXORUBICIN DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFUSION; KAPOSI SARCOMA; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC AGENTS; CD4 LYMPHOCYTE COUNT; DOXORUBICIN; DRUG CARRIERS; HIV-1; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; LONG-TERM CARE; MALE; RNA, VIRAL; SARCOMA, KAPOSI; SURVIVAL ANALYSIS;

EID: 0035050644     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00053-3     Document Type: Article

References (20)

1. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
2. AIDS-associated Kaposi's sarcoma
3. Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS)
4. AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis
5. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma
6. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome
7. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma
8. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
9. Development of liposomal anthracyclines: From basics to clinical applications
10. Ultrasound as a tool to evaluate remission of cutaneous Kaposi sarcoma
11. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
12. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma
13. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
14. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
15. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
16. Fatal hepatic failure with liposomal doxorubicin
17. Hepatotoxicity associated with antiretroviral therapy in adults with HIV and the role of hepatitis B or C infection
18. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma
19. Combination antiretroviral therapy and incidence of AIDS-related malignancies
20. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin